Cancer Therapeutics and Biotherapeutics Market Size, Key Companies, Company Market Share, Patient Volume, Treatment Adoption Rates, Pricing Analysis, Regulatory Landscape, Competitive Positioning, and Demand Forecast

Revenue, 2025

USD 210.73 billion

Forecast Year, 2035

USD 475.26 billion

CAGR, 2026 - 2035

8.47%

Report Coverage

Global

What is the Cancer Therapeutics and Biotherapeutics Market Size?

The global cancer therapeutics and biotherapeutics market size accounted for USD 210.73 billion in 2025 and is expected to exceed around USD 475.26 billion by 2035, growing at a CAGR of 8.47% from 2026 to 2035. The key players operating in the market are focused on adopting inorganic growth strategies like acquisition and merger to develop cancer therapeutics and biotherapeutics which is estimated to drive the global cancer therapeutics and biotherapeutics market over the forecast period.

Cancer Therapeutics and Biotherapeutics Market Key Takeaways

• North America dominated the global market with the largest market share of 41% in 2025.
• Asia Pacific is projected to expand at the notable CAGR during the forecast period.
• By application, the lung cancer segment contributed the highest market share in 2025.
• By application, the head and neck cancer segments is estimated to be the fastest-growing segment during the forecast period.
• By top selling drugs, the revlimid segment has held the largest market share in 2025.
• By top selling drugs, the zytiga segments is predicted to be the fastest-growing segment during the forecast period.

How Can AI Improve Cancer Therapeutics?

The integration of artificial intelligence assists in drug discovery and development. AI assists in analyzing large datasets to identify potential drug candidates, predict their efficacy, and optimize drug design, significantly reducing the time and cost associated with traditional drug discovery processes. AI algorithms helps in analyzing patient data, including genetic information, to develop personalized treatment plans. This approach ensures that patients receive therapies tailored to their specific genetic makeup and cancer type, improving treatment outcomes.

AI-powered chatbots and virtual assistants has ability to provide patients with information, support, and reminders about their treatment plans, improving adherence and overall patient experience. By automating complex tasks and enhancing decision-making processes, AI can help reduce the costs associated with drug development, clinical trials, and patient care.

Cancer Therapeutics and Biotherapeutics Market Growth Factors

• Increasing number of regulatory approvals for new cancer drugs and therapies enhances cancer therapeutics and biotherapeutics market expansion.
• Advances in diagnostic technologies enable earlier detection of cancer, increasing the need for effective therapeutic options, which has driven the market growth.
• The shift towards tailored treatments based on genetic and molecular profiles of patients is driving the development and adoption of targeted therapies.
• Strategic collaborations between biotech firms, research institutions, and pharmaceutical companies are fostering innovation and accelerating the development of new cancer treatments.
• Increased awareness about cancer and the availability of treatment options, along with advocacy for better healthcare access, are contributing to cancer therapeutics and biotherapeutics market growth.
• Growing healthcare spending in both developed and emerging economies supports the adoption of advanced cancer therapies.

Market Scope

The favorable government regulations and guidelines for the treatment of cancer is driving the growth of the global cancer therapeutics and biotherapeutics market. The number of drug manufacturers is involved in the manufacturing process of cancer therapeutics and biotherapeutics. The key market players are constantly adopting the marketing strategies for the growth and development of cancer therapeutics and biotherapeutics market.

Nowadays, the approvals on the drugs and medications by Food and Drug Administration (FDA) are quite easy. This factor is encouraging market players to develop new products in the cancer therapeutics and biotherapeutics market. Moreover, the market players are collaborating with logistics companies for supplying drugs and medicines on an international level. This factor is supporting the growth of the global cancer therapeutics and biotherapeutics market over the forecast period.

Segment Insights

Application Insights

The lung cancer segment dominated the cancer therapeutics and biotherapeutics market in 2025. The lung cancer is the most common cancer killer, accounting for about a quarter of all cancer fatalities. The lung cancer kills more people than breast cancer, colon cancer, and prostate cancer combined every year. Thus, the lung cancer segment is growing at a rapid pace.

The head and neck cancer segment is fastest growing segment of the cancer therapeutics and biotherapeutics market in 2022. The rising incidences of cancer are driving the segment growth. In the U.S., head and neck cancer accounts for around 4% of all cancers. Thus, this factor is driving the growth of the segment over the projected period.

Top Selling Drugs Insights

The Revlimid segment dominated the cancer therapeutics and biotherapeutics market in 2025. The Revlimid is used in the treatment of wide range of cancers. This drug helps to increase the life expectancy rate of cancer patients. In addition, Revlimid contains lenalidomide, which treat myeloma and myelodysplastic syndrome. As a result, the growing prevalence of cancer disorders is driving the growth of the segment.

The Zytiga segment is fastest growing segment of the cancer therapeutics and biotherapeutics market in 2022. Zytiga contains abiraterone acetate which is mainly used in the treatment of the prostate cancer. This drug is approved by Food and Drug Administration (FDA). The doctors recommend to avoid overdoses of Zytiga. This can also lead to death and fatalities.

Product Type Insights

Which Product Type Segment Dominated the Cancer Therapeutics and Biotherapeutics Market?

The chemotherapy segment held a dominant position in the market in 2025 due to the growing need for cost-effective medications. Chemotherapy can usually be given through oral or parenteral routes, making it highly feasible for patients and providers. It eliminates the need for any specialized instrument or equipment for its administration. Chemotherapy enhances patient adherence, reducing the chances of missing a dose.

The biotherapy segment is expected to grow with the highest CAGR in the market during the studied years due to the growing demand for targeted therapeutics and personalized medicines. Biological therapies directly help the body's immune cells identify and kill cancer cells. CAR T-cell therapy, cancer vaccines, and immune checkpoint inhibitors are some examples of biotherapy. Biotherapy is estimated to be more effective than chemotherapy.

End User Insights

How the Hospital Segment Dominated the Cancer Therapeutics and Biotherapeutics Market?

The hospital segment contributed the biggest market share in 2025 due to the presence of advanced infrastructure and increasing investments. Patients prefer visiting hospitals as they have trained professionals from various subjects, providing multidisciplinary expertise. Hospitals possess the necessary medical devices and drugs required to administer to a patient. The availability of a favorable reimbursement policy and stringent regulatory policies foster the segment's growth.

The household segment is expected to expand rapidly in the market in the coming years due to the growing geriatric population and the need for home healthcare. Healthcare professionals and other staff provide personalized care to patients in the comfort of their homes. The segmental growth is also attributed to overcrowded cancer centers, rising treatment costs, and a growing need for long-term symptom and supportive care.

Regional Insights

Which Factors Drive the Cancer Therapeutics and Biotherapeutics Market in North America?

North America held a major market share in 2025 due to advanced healthcare infrastructure and the presence of key players. People are becoming increasingly aware of advanced treatments through the availability of favorable reimbursement policies by government and private organizations. Countries like the U.S. and Canada are at the forefront of conducting extensive research and clinical trials in the region.

U.S. Cancer Therapeutics and Biotherapeutics Market Size and Growth 2026 to 2035

The U.S. cancer therapeutics and biotherapeutics market size was evaluated at USD 60.48 billion in 2025 and is projected to be worth around USD 139.15 billion by 2035, growing at a CAGR of 8.69% from 2026 to 2035.

U.S. Market Trends

The U.S. leads the market in North America due to favorable government support. The U.S. government has launched several initiatives to support cancer care. The National Cancer Institute (NCI) is the federal government's agency for conducting research and training for cancer treatment. The U.S. Food and Drug Administration (FDA) regulates the approval of innovative cancer therapeutics and biotherapeutics.

How is Asia-Pacific Growing in the Cancer Therapeutics and Biotherapeutics Market?

Asia-Pacific is expected to experience the fastest growth during the predicted timeframe due to growing research and development activities and burgeoning healthcare infrastructure. The rising prevalence of cancer, increasing biotech investments, and growing clinical trial activities augment the market. Government bodies make constant efforts to establish a robust manufacturing infrastructure, encouraging foreign companies to build their manufacturing facilities in the region.

China Market Trends

China is emerging as a global biotech hub, driven by increasing venture capital investments and a rising number of patents. Between 2019 and 2023, China raised around $26 billion in biopharma private equity/venture capital investment. The annual biotech investment rose from $3.7 billion in 2023 to $6.8 billion in 2025.

How is Europe Growing in the Cancer Therapeutics and Biotherapeutics Market?

Europe is expected to grow at a notable CAGR in the foreseeable future due to evolving regulatory landscapes and favorable government initiatives. The European Medicines Agency (EMA) is the main regulatory authority for cancer therapeutics and biotherapeutics. In 2024, about 28% of all medicines approved with new active substances were for cancer. The presence of key players and the growing demand for personalized medicines augment the market.

UK Market Trends

The UK market is driven by key academic institutions and dedicated government funding like UK Cancer Research Institute. These activities support the development of targeted immunotherapies, cell engagers, and biologics. The Life Sciences sector raised more than £3 billion in new public-private investment to support new treatments and advances.

Cancer Therapeutics and Biotherapeutics Market Companies

• Amgen Inc.
• Bristol-Myers Squibb
• Celgene Corporation
• ELI Lilly and Company
• Hoffmann-La Roche AG
• EnGeneIC Ltd
• Merck & Co Inc.
• Novartis
• Pfizer Inc.
• Johnson & Johnson

Key Developments

• In September, 2024, Oracle, computer software company revealed the Trends in CancerMPact Treatment Architecture. With the use of the new cloud-based tool, pharmaceutical companies can now examine global and historical patterns of cancer treatment to assess the effects of market events, including the approval of new drugs, and the adoption of drugs and therapeutic classes. The newest module in CancerMPact, a thorough oncology decision assistance tool, is called Treatment Architecture Trends. It can be applied to strategic planning, market sizing and analysis, and the discovery of business prospects in the US, Europe, Japan, and China. The cloud-based integrated Future Trends and Insights, CancerLandscape, and Treatment Architecture modules are also part of the CancerMPact platform.
• In January, 2025, according to Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") and its oncology-focused subsidiary, Citius Oncology significant progress has been made in getting ready for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). With plans to introduce LYMPHIR in the first half of 2025, management is committed to providing patients with access to the medication as soon as possible.

Segments Covered in the Report

By Application

• Blood Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Breast Cancer
• Cervical Cancer
• Head and Neck Cancer
• Giloblastoma
• Malignant Meningioma
• Mesothelioma
• Melanoma
• Others

By Top Selling Drugs

• Revlimid
• Avastin
• Herceptin
• Rituxan
• Opdivo
• Gleevec
• Velcade
• Imbruvica
• Ibrance
• Zytiga
• Alimta
• Xtandi
• Tarceva
• Perjeta
• Termodar
• Others

By Product Type

• Chemotherapy
• Radiation Therapy
• Hormone Therapy
• Biotherapy
• Others

By End User

• Consumption (Sales)
• Household
• Hospital

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa